The Global Sepsis Alliance has stated that the novel coronavirus may lead to sepsis by affecting the body’s immune system response toward the infection, resulting in organ damage and even death. Such developments are creating revenue opportunities for stakeholders in the sepsis treatment market. COVID-19 pneumonia is one of the major factors to cause sepsis in patients, owing to severe lung inflammation that occurs in response to the novel infection.
Bacterial, fungal, and viral infections have the possibility to cause coronavirus pneumonia, thus leading to sepsis. It has been found that patients with severe COVID-19 from Seattle reported severe septic shock, which triggered the demand for drugs to support heart and blood circulation. This has compelled companies in the sepsis treatment market to ensure the availability of treatments and medical supplies to improve patient quality of life.
Continuous Renal Replacement Therapy (CRRT) is considered as the gold standard for sepsis syndromes. However, complications of CRRT such as risks associated with intravascular lines such as hemorrhage, infection or thrombosis need to be communicated to the patient or the family, while considering initiation. Stakeholders in the sepsis treatment market are working closely with healthcare professionals to troubleshoot problems of CRRT by considering factors including severity of illness and necessity of the procedure to reduce morbidity and mortality rates.
CRRT is linked with electrolyte disturbances and hypothermia in patients. Hence, clinicians are considering various factors such as judging the severity of acute kidney injury (AKI) and the presence of electrolyte or acid-base disorders to improve medical outcomes.
The global sepsis treatment market is expected to reach US$ 1.6 Bn by the end of 2031. The high number of sepsis patients in the U.S. is creating stable revenue streams for stakeholders. Though CRRT dominates most sepsis procedures in intensive care units (ICUs), there is a significant demand for intermittent hemodialysis (IHD) for the treatment of patients.
Anticoagulation is required for renal replacement therapy (RRT) to prevent clotting of the extracorporeal circuit. On the other hand, systematic heparin anticoagulation is commonly used during IHD. However, this procedure increases the risk of bleeding and results in high ICU mortality rates. In order to overcome this issue, companies in the sepsis treatment market are offering heparin-free RRT anticoagulation strategy for patients.
The European Sepsis Academy (ESA-ITN) is gaining recognition for advancements in sepsis diagnosis and treatment. This research project involves a training network that assists in diagnosis of sepsis through biomarker diagnostics and clinical trial models. Companies in the sepsis treatment market are taking cues from such research projects and collaborating with researchers to gain information on pathogenesis of sepsis-induced immune suppression and the development of diagnostic platforms.
Companies in the sepsis treatment market are increasing their research in identification and validation of diagnostic markers. They are gaining emphasis on regulatory mechanisms that drive inflammation and immunosuppression during sepsis.
The sepsis deep learning technology is expected to bring a significant change in the global sepsis treatment market. This has led to the popularity of Sepsis Watch, which was developed in November 2018, and serves as a sepsis detection and management platform that can be used by clinicians to improve compliance with recommended treatment guidelines for sepsis. However, there is a need for new mechanisms of trust and accountability that must be developed to ensure that the systems are safe and reliable. Such platforms hold promising potentials to improve patient outcomes and create value grab opportunities for companies in the sepsis treatment market.
Analysts’ Viewpoint
The COVID-19 pandemic has resulted in high mortality of patients who were previously and are currently diagnosed with sepsis. CRRT has the potential to prevent worsening of cerebral edema in patients. However, CRRT is associated with electrolyte disturbances and hypotention. Hence, stakeholders in the sepsis treatment market should increase awareness about the adoption of an inter-professional approach to provide safe and efficient CRRT in patients and reduce incidence of complications. Companies in the sepsis treatment market are increasing efforts to learn the health system framework and previously described best practices for bringing in routine and responsible machine learning (ML) in healthcare. They should collaborate with researchers to prevent post-sepsis sequelae and post-sepsis pathways to optimize treatment.
Sepsis Treatment Market – Segmentation
Type |
|
Therapy |
|
End User |
|
Region |
|
Sepsis treatment market was valued over US$ 600 Mn in 2020 and is expected to reach US$ 1.6 Bn by the end of 2031
Sepsis treatment market is driven by increase in number of product launches and collaborations among players
The severe sepsis segment accounted for significant share of the global sepsis treatment market, the segment's dominance can be attributed to increase in patient population with infectious diseases such as COVID-19
The hospitals segment accounted for major share of the sepsis treatment market, hospitals are an important channel for sepsis treatment
Key players in the global sepsis treatment market include Baxter International, Inc., Fresenius Medical Care AG & Co. KGaA, Nipro Corporation, Asahi Kasei, B. Braun Group, CytoSorbents Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sepsis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sepsis Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Sepsis Population (admissions as % of population)
5.2. Total Sepsis Hospital Admissions [general ward & other, ICU patients admitted (000)]
5.3. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Sepsis Treatment Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Sepsis Treatment Market Value (US$ Bn) Forecast, by Type, 2017–2031
6.3.1. Severe Sepsis
6.3.2. Septic Shock
6.3.3. Sepsis in Need of Blood Purification
6.4. Global Sepsis Treatment Market Attractiveness Analysis, by Type
7. Global Sepsis Treatment Market Analysis and Forecast, by Therapy
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
7.3.1. Continuous Renal Replacement Therapies (CRRT)
7.3.2. Intermittent Hemodialysis
7.3.3. Sustained Low-efficiency Daily Dialysis (SLEDD)
7.3.4. Others
7.4. Global Sepsis Treatment Market Attractiveness Analysis, by Therapy
8. Global Sepsis Treatment Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Sepsis Treatment Market Value (US$ Bn) Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Specialty Centers
8.3.3. Others
8.4. Global Sepsis Treatment Market Attractiveness Analysis, by End-user
9. Global Sepsis Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Sepsis Treatment Market Value (US$ Bn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Sepsis Treatment Market Attractiveness Analysis, by Region
10. North America Sepsis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Sepsis Treatment Market Value (US$ Bn) Forecast, by Type , 2017–2031
10.2.1. Severe Sepsis
10.2.2. Septic Shock
10.2.3. Sepsis in Need of Blood Purification
10.3. North America Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
10.3.1. Continuous Renal Replacement Therapies (CRRT)
10.3.2. Intermittent Hemodialysis
10.3.3. Sustained Low-efficiency Daily Dialysis (SLEDD)
10.3.4. Others
10.4. North America Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
10.4.1. Hospitals
10.4.2. Specialty Centers
10.4.3. Others
10.5. North America Sepsis Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Sepsis Treatment Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Therapy
10.6.3. By End-user
10.6.4. By Country
11. Europe Sepsis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Sepsis Treatment Market Value (US$ Bn) Forecast, by Type, 2017–2031
11.2.1. Severe Sepsis
11.2.2. Septic Shock
11.2.3. Sepsis in Need of Blood Purification
11.3. Europe Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
11.3.1. Continuous Renal Replacement Therapies (CRRT)
11.3.2. Intermittent Hemodialysis
11.3.3. Sustained Low-efficiency Daily Dialysis (SLEDD)
11.3.4. Others
11.4. Europe Sepsis Treatment Market Value (US$ Bn) Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Specialty Centers
11.4.3. Others
11.5. Europe Sepsis Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Sepsis Treatment Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Therapy
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Sepsis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Sepsis Treatment Market Value (US$ Bn) Forecast, by Type, 2017–2031
12.2.1. Severe Sepsis
12.2.2. Septic Shock
12.2.3. Sepsis in Need of Blood Purification
12.3. Asia Pacific Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
12.3.1. Continuous Renal Replacement Therapies (CRRT)
12.3.2. Intermittent Hemodialysis
12.3.3. Sustained Low-efficiency Daily Dialysis (SLEDD)
12.3.4. Others
12.4. Asia Pacific Sepsis Treatment Market Value (US$ Bn) Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Specialty Centers
12.4.3. Others
12.5. Asia Pacific Sepsis Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Sepsis Treatment Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Therapy
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Sepsis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Sepsis Treatment Market Value (US$ Bn) Forecast, by Type, 2017–2031
13.2.1. Severe Sepsis
13.2.2. Septic Shock
13.2.3. Sepsis in Need of Blood Purification
13.3. Latin America Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
13.3.1. Continuous Renal Replacement Therapies (CRRT)
13.3.2. Intermittent Hemodialysis
13.3.3. Sustained Low-efficiency Daily Dialysis (SLEDD)
13.3.4. Others
13.4. Latin America Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
13.4.1. Hospitals
13.4.2. Specialty Centers
13.4.3. Others
13.5. Latin America Sepsis Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Sepsis Treatment Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Therapy
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Sepsis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Sepsis Treatment Market Value (US$ Bn) Forecast, by Type, 2017–2031
14.2.1. Severe Sepsis
14.2.2. Septic Shock
14.2.3. Sepsis in Need of Blood Purification
14.3. Middle East & Africa Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
14.3.1. Continuous Renal Replacement Therapies (CRRT)
14.3.2. Intermittent Hemodialysis
14.3.3. Sustained Low-efficiency Daily Dialysis (SLEDD)
14.3.4. Others
14.4. Middle East & Africa Sepsis Treatment Market Value (US$ Bn) Forecast, by Therapy, 2017–2031
14.4.1. Hospitals
14.4.2. Specialty Centers
14.4.3. Others
14.5. Middle East & Africa Sepsis Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Sepsis Treatment Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Therapy
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competitive Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Baxter International, Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Strategic Overview
15.2.1.5. SWOT Analysis
15.2.2. Fresenius Medical Care AG & Co. KGaA
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Strategic Overview
15.2.2.5. SWOT Analysis
15.2.3. Nipro Corporation
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Strategic Overview
15.2.3.5. SWOT Analysis
15.2.4. Asahi Kasei
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Strategic Overview
15.2.4.5. SWOT Analysis
15.2.5. B. Braun Group
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Strategic Overview
15.2.5.4. SWOT Analysis
15.2.6. CytoSorbents Corporation
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. Medtronic plc
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Strategic Overview
15.2.7.5. SWOT Analysis
15.2.8. Nikkiso Co., Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Strategic Overview
15.2.8.5. SWOT Analysis
15.2.9. Medica SPA
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Strategic Overview
15.2.9.5. SWOT Analysis
15.2.10. Toray Industries
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Strategic Overview
15.2.10.5. SWOT Analysis
15.2.11. Merck & Co., Inc.
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Financial Overview
15.2.11.3. Product Portfolio
15.2.11.4. Strategic Overview
15.2.11.5. SWOT Analysis
List of Tables
Table 01: Global Sepsis Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Sepsis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 03: Global Sepsis Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Sepsis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Sepsis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Sepsis Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 07: North America Sepsis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 08: North America Sepsis Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Sepsis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Sepsis Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 11: Europe Sepsis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 12: Europe Sepsis Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Sepsis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Sepsis Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Asia Pacific Sepsis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 16: Asia Pacific Sepsis Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Sepsis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Sepsis Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 19: Latin America Sepsis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 20: Latin America Sepsis Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Sepsis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Sepsis Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Middle East & Africa Sepsis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031
Table 24: Middle East & Africa Sepsis Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Sepsis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Sepsis Treatment Market Value Share, by Type, 2020
Figure 03: Global Sepsis Treatment Market Value Share, by Therapy, 2020
Figure 04: Global Sepsis Treatment Market Value Share, by End-user, 2020
Figure 05: Global Sepsis Treatment Market Value Share, by Region, 2020
Figure 06: Global Sepsis Treatment Market Value Share Analysis, by Type, 2020 and 2031
Figure 07: Global Sepsis Treatment Market Attractiveness Analysis, by Type, 2021–2031
Figure 08: Global Sepsis Treatment Market Revenue (US$ Mn), by Severe Sepsis/Sepsis, 2017–2031
Figure 09: Global Sepsis Treatment Market Revenue (US$ Mn), by Septic Shock, 2017–2031
Figure 10: Global Sepsis Treatment Market Revenue (US$ Mn), by Sepsis in Need of Blood Purification, 2017–2031
Figure 11: Global Sepsis Treatment Market Value Share Analysis, by Therapy, 2020 and 2031
Figure 12: Global Sepsis Treatment Market Attractiveness Analysis, by Therapy, 2021–2031
Figure 13: Global Sepsis Treatment Market Revenue (US$ Mn), by Continuous Renal Replacement Therapies (CRRT), 2017–2031
Figure 14: Global Sepsis Treatment Market Revenue (US$ Mn), by Intermittent Hemodialysis, 2017–2031
Figure 15: Global Sepsis Treatment Market Revenue (US$ Mn), by Sustained Low-efficiency Daily Dialysis (SLEDD), 2017–2031
Figure 16: Global Sepsis Treatment Market Revenue (US$ Mn), by Others, 2017–2031
Figure 17: Global Sepsis Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 18: Global Sepsis Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 19: Global Sepsis Treatment Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 20: Global Sepsis Treatment Market Revenue (US$ Mn), by Specialty Centers, 2017–2031
Figure 21: Global Sepsis Treatment Market Revenue (US$ Mn), by Others, 2017–2031
Figure 22: Global Sepsis Treatment Market Value Share Analysis, by Region, 2020 and 2031
Figure 23: Global Sepsis Treatment Market Attractiveness Analysis, by Region, 2021–2031
Figure 24: North America Sepsis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 25: North America Sepsis Treatment Market Value Share Analysis, by Country, 2020 and 2031
Figure 26: North America Sepsis Treatment Market Attractiveness Analysis, by Country, 2021–2031
Figure 27: North America Sepsis Treatment Market Value Share Analysis, by Type, 2020 and 2031
Figure 28: North America Sepsis Treatment Market Attractiveness Analysis, by Type, 2021–2031
Figure 29: North America Sepsis Treatment Market Value Share Analysis, by Therapy, 2020 and 2031
Figure 30: North America Sepsis Treatment Market Attractiveness Analysis, by Therapy, 2021–2031
Figure 31: North America Sepsis Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 32: North America Sepsis Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 33: Europe Sepsis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 34: Europe Sepsis Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 35: Europe Sepsis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 36: Europe Sepsis Treatment Market Value Share Analysis, by Type, 2020 and 2031
Figure 37: Europe Sepsis Treatment Market Attractiveness Analysis, by Type, 2021–2031
Figure 38: Europe Sepsis Treatment Market Value Share Analysis, by Therapy, 2020 and 2031
Figure 39: Europe Sepsis Treatment Market Attractiveness Analysis, by Therapy, 2021–2031
Figure 40: Europe Sepsis Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 41: Europe Sepsis Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 42: Asia Pacific Sepsis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 43: Asia Pacific Sepsis Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 44: Asia Pacific Sepsis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 45: Asia Pacific Sepsis Treatment Market Value Share Analysis, by Type, 2020 and 2031
Figure 46: Asia Pacific Sepsis Treatment Market Attractiveness Analysis, by Type, 2021–2031
Figure 47: Asia Pacific Sepsis Treatment Market Value Share Analysis, by Therapy, 2020 and 2031
Figure 48: Asia Pacific Sepsis Treatment Market Attractiveness Analysis, by Therapy, 2021–2031
Figure 49: Asia Pacific Sepsis Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 50: Asia Pacific Sepsis Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 51: Latin America Sepsis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 52: Latin America Sepsis Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 53: Latin America Sepsis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 54: Latin America Sepsis Treatment Market Value Share Analysis, by Type, 2020 and 2031
Figure 55: Latin America Sepsis Treatment Market Attractiveness Analysis, by Type, 2021–2031
Figure 56: Latin America Sepsis Treatment Market Value Share Analysis, by Therapy, 2020 and 2031
Figure 57: Latin America Sepsis Treatment Market Attractiveness Analysis, by Therapy, 2021–2031
Figure 58: Latin America Sepsis Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 59: Latin America Sepsis Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 60: Middle East & Africa Sepsis Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 61: Middle East & Africa Sepsis Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 62: Middle East & Africa Sepsis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 63: Middle East & Africa Sepsis Treatment Market Value Share Analysis, by Type, 2020 and 2031
Figure 64: Middle East & Africa Sepsis Treatment Market Attractiveness Analysis, by Type, 2021–2031
Figure 65: Middle East & Africa Sepsis Treatment Market Value Share Analysis, by Therapy, 2020 and 2031
Figure 66: Middle East & Africa Sepsis Treatment Market Attractiveness Analysis, by Therapy, 2021–2031
Figure 67: Middle East & Africa Sepsis Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 68: Middle East & Africa Sepsis Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 69: Global Sepsis Treatment Market Share, by Company, 2019
Figure 70: Baxter International, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 71: Fresenius Medical Care AG & Co. KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 72: Nipro Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 73: Asahi Kasei Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 74: B. Braun Group Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 75: CytoSorbents Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 76: Medtronic Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 77: NIKKISO CO., LTD Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 78: Toray Industries Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019
Figure 79: Merck & Co. Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019